Prostate cancer
NEW --- Sequencing treatments in mCRPC patients without HRR gene mutationsCase 1: Jens (68 years old)
Jens is a 68-year-old retired firefighter. As a volunteer, he still leads meetings to provide tips to prevent fire at home. He was earlier diagnosed with high-risk PCa (cT3N0M0; ISUP grade 4; PSA 18 ng/ml). He was treated with EBRT + 24 months ADT. His PSA nadir was 0.7 ng/ml.
2 years after completion of ADT:
- PSA: 3.1 ng/ml
- Testosterone: 312 ng/dl (10.8 nmol/l)
- CT scan: enlarged pelvic lymph nodes
- Bone scan: negative
ADT was started again. PSA nadir was 0.9 ng/ml.
18 months after start of ADT:
- PSA: 7.6 ng/ml
- Bone scan: 3 bone metastases; treatment with denosumab was started
- Moderate pain; well controlled by NSAIDs
- ALP: 132 U/l
- Serum testosterone: 12 ng/dl (0.42 nmol/l)
- CT scan: stable lymph nodes, no signs of visceral metastasis
- ECOG PS: 1
- No germline and/or somatic HRR/BRCA mutation identified